Is Alkermes Poised for a Comeback in 2017?
And that was the good news for investors. At one point, the stock had lost two-thirds of its value after two phase 3 trials failed.
from Biotech News
And that was the good news for investors. At one point, the stock had lost two-thirds of its value after two phase 3 trials failed.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments